Relapse study group parameters (n = 45)
| Parameter . | No. (%) or median (range) . |
|---|---|
| Sex | Male, 25 (56%); female, 20 (44%) |
| Age, y | 32 (1-68)* |
| WBC, × 103/μL | 6.8 (0.6-143)† |
| APL cytologic type‡ | M3, 37 (82%); M3 variant, 6 (13%) |
| PML-RARα type | S-isoform, 29 (64%); L-isoform, 16 (36%) |
| Days to relapse | 528 (134-1431) |
| ATRA status at relapse§ | On-ATRA, 20 (44%); Off-ATRA, 25 (56%) |
| Postrelapse death‖ | Alive, 30 (67%); dead, 15 (33%) |
| Parameter . | No. (%) or median (range) . |
|---|---|
| Sex | Male, 25 (56%); female, 20 (44%) |
| Age, y | 32 (1-68)* |
| WBC, × 103/μL | 6.8 (0.6-143)† |
| APL cytologic type‡ | M3, 37 (82%); M3 variant, 6 (13%) |
| PML-RARα type | S-isoform, 29 (64%); L-isoform, 16 (36%) |
| Days to relapse | 528 (134-1431) |
| ATRA status at relapse§ | On-ATRA, 20 (44%); Off-ATRA, 25 (56%) |
| Postrelapse death‖ | Alive, 30 (67%); dead, 15 (33%) |
For complete data on all 45 relapse patients, see supplemental Table 3.
Distribution: < 15 years, 11; 15-60 years, 28; and > 60 years, 6.
Distribution: < 5 × 103/μL, 43%; 5-10 ×103/μL, 16%; > 10 ×103/μL, 41%.
French-American-British subclassification ×103; 2 patients could not be subclassified.
On-ATRA, relapse within 30 days of last ATRA dose; Off-ATRA, relapse > 30 days after last ATRA dose (actual range, 86-966 days).
Median follow-up of surviving patients = 71 months.